Bill Haney, Skyhawk CEO (Dave Pedley/Getty Images for SXSW)

Bill Haney's lat­est start­up scores deal from Sanofi, its newest Big Phar­ma part­ner, with $54M up­front

A heav­i­ly fi­nanced biotech look­ing to drug RNA with small mol­e­cules is adding yet an­oth­er com­pa­ny to its Big Phar­ma short­list.

Sky­hawk Ther­a­peu­tics, the biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.